Thursday, October 29, 2026

Hyperscalers Line Up $650B in 2026 AI Capex as Vertiv, Nvidia Build 800-Volt Power Systems

Four AI hyperscalers plan roughly $650 billion in combined 2026 capital spending, with Alphabet raising its own 2026 capex outlook. Vertiv and Nvidia are co-developing 800-volt DC power platforms to keep pace with data center energy demand, pulling infrastructure vendors into multi-year AI buildout commitments.

LM Salvado

July 30, 2026

Hyperscalers Line Up $650B in 2026 AI Capex as Vertiv, Nvidia Build 800-Volt Power Systems
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Four AI hyperscalers plan roughly billions in combined capital expenditure for 2026.1 Alphabet raised its own 2026 capex outlook in the same window.1 The two moves confirm hyperscalers are not slowing AI infrastructure spending despite elevated interest rates.1

Vertiv partnered with Nvidia on next-generation 800-volt DC power platforms for AI data centers.1 The higher-voltage architecture is designed to move more power through data center racks with less energy loss. AI chip clusters draw far more electricity than prior computing generations, and power delivery has become a bottleneck for deployment speed.

The pairing of hyperscaler capex guidance with vendor-level engineering commitments signals a structural shift. Power and cooling suppliers are no longer reacting to AI demand after the fact. They are being drawn into multi-year design partnerships tied directly to chip roadmaps.1

The trend points to continued upward guidance revisions from hyperscalers through the rest of 2026.1 Semiconductor makers, power management firms, and data center REITs sit downstream of that spending. Companies in the Nvidia and Vertiv supply chain are positioned for capex-driven revenue beats as this cycle continues.1

Three data points reinforce each other here. Hyperscaler spending guidance is rising, not falling. A major infrastructure vendor is co-engineering next-generation power hardware specifically for AI workloads. And the scale of committed spending, near billions across four companies for one year, sets a floor for how much physical infrastructure must be built regardless of near-term rate conditions.1

For hardware vendors, the shift from selling components to co-designing power platforms marks a change in how deeply AI demand is reshaping data center engineering. Electrical systems built around chips still years from mass deployment are now in active development, a sign that infrastructure planning has moved from reactive procurement to long-horizon architecture commitments.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com